FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Fisher

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Jennifer A Kanakry; MARIO LEMAS; Hailun Li; Thomas P Miller; Patrick Stiff; King L Tan; Ranjana Advani; Nancy L Bartlett; Bruce D Cheson; Richard I Fisher; Randy D Gascoyne; Lan L Gellert; Leo I Gordon; Fangxin Hong; Sandra J Horning; wen son hsieh; Brad S Kahl; Richard F Ambinder
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.
Girija Dasmahapatra; Paul Dent; Richard I Fisher; Jonathan Friedberg; Hiral Patel; Steven Grant
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Oliver W Press; Lisa M Rimsza; Catherine Spier; Joseph M Unger; Rita M Braziel; Bruce D Cheson; Myron S Czuczman; Shaker R Dakhil; Jonathan W Friedberg; Ajay K Gopal; Mark S Kaminski; Michael LeBlanc; David G Maloney; Thomas P Miller; Richard I Fisher
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Fisher (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jennifer A Kanakry; MARIO LEMAS; Hailun Li; Thomas P Miller; Patrick Stiff; King L Tan; Ranjana Advani; Nancy L Bartlett; Bruce D Cheson; Richard I Fisher; Randy D Gascoyne; Lan L Gellert; Leo I Gordon; Fangxin Hong; Sandra J Horning; wen son hsieh; Brad S Kahl; Richard F Ambinder
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.
Blood 2013;121(18):3547-53.
2013: Girija Dasmahapatra; Paul Dent; Richard I Fisher; Jonathan Friedberg; Hiral Patel; Steven Grant
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
British journal of haematology 2013;161(1):43-56.
2013: Oliver W Press; Lisa M Rimsza; Catherine Spier; Joseph M Unger; Rita M Braziel; Bruce D Cheson; Myron S Czuczman; Shaker R Dakhil; Jonathan W Friedberg; Ajay K Gopal; Mark S Kaminski; Michael LeBlanc; David G Maloney; Thomas P Miller; Richard I Fisher
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):314-20.
2013: Daruka Mahadevan; Richard I Fisher; Michael LeBlanc; Daniel O Persky; Catherine M Spier; Joseph M Unger; Fay Young; Thomas P Miller
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
Cancer 2013;119(2):371-9.
2012: King L Tan; Ranjana H Advani; Nancy L Bartlett; Rena Buckstein; Joseph Michael Connors; Richard I Fisher; Leo I Gordon; Fangxin Hong; Sandra J Horning; Brad S Kahl; Lisa M Rimsza; David W Scott; Christian Steidl; Randy D Gascoyne
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.
Blood 2012;120(16):3280-7.
2012: Roland Schmitz; Arthur L Shaffer; Erlend B Smeland; Raymond R Tubbs; Thomas A Waldmann; Dennis D Weisenburger; Wyndham Wilson; George Wright; Wenming Xiao; Weihong Xu; Yandan Yang; Ryan M Young; Meili Zhang; Hong Zhao; Rita M Braziel; Eric Buras; Elias Campo; Michele Ceribelli; Wing C Chan; Joseph Michael Connors; James R Cook; Jan Delabie; Richard I Fisher; Randy D Gascoyne; Daniel J Hodson; Elaine S Jaffe; Sameer Jhavar; Philip Kluin; Holger Kohlhammer; Xuelu Liu; Sam M Mbulaiteye; Hans Konrad Müller-Hermelink; Martin D Ogwang; German Ott; Stefania Pittaluga; John Powell; Steven J Reynolds; Alan B Rickinson; Lisa M Rimsza; Andreas Rosenwald; Martin Rowe; Louis M Staudt
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature 2012;490(7418):116-20.
2012: Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; Brent Farnsworth; Richard I Fisher; Martha J Glenn; Maria Iannone; Michael LeBlanc; Thomas P Miller
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Blood 2012;120(6):1210-7.
2012: Daniel O Persky; Oliver W Press; Rita M Braziel; David Dornan; Richard I Fisher; Bryan H Goldman; Michael LeBlanc; David G Maloney; Thomas P Miller; Lisa M Rimsza
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Haematologica 2012;97(6):937-42.
2012: Girija Dasmahapatra; Paul Dent; Richard I Fisher; Jonathan W Friedberg; Dmitry Lembersky; Hiral Patel; Derick Peterson; Minkyeong P Son; Elisa Attkisson; Steven Grant
Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Molecular cancer therapeutics 2012;11(5):1122-32.
2012: Daruka Mahadevan; Ann Manziello; Thomas P Miller; Carla Morales; Daniel O Persky; Laurence S Cooke; Richard I Fisher; Amy Stejskal; Wenqing Qi
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(8):2210-9.
2012: Sarah F Keller; Jennifer L Kelly; Jane Liesveld; Jamie Oliva; Gordon Phillips; Lynn Rich; Elizabeth Sensenig; Jennifer Andreozzi; Michael Becker; Steven H Bernstein; Louis Constine; Richard I Fisher; Jonathan W Friedberg
Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012;18(4):640-7.
2012: Mark Kirschbaum; Lisa M Rimsza; Jasmine Zain; James R Cook; Stephen J Forman; Bryan H Goldman; Richard I Fisher
A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.
Leukemia & lymphoma 2012;53(2):259-62.
2011: Girija Dasmahapatra; Paul Dent; Richard I Fisher; Jonathan W Friedberg; Dmitry Lembersky; Minkyeong P Son; Elisa Attkisson; Steven Grant
Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
Molecular cancer therapeutics 2011;10(9):1686-97.
2011: Daruka Mahadevan; Richard I Fisher
Novel therapeutics for aggressive non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(14):1876-84.
2011: Richard I Fisher
Advanced insights into the biology of malignant lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(14):1799-800.
2011: Jonathan W Friedberg; Julie M Vose; Jennifer L Kelly; Faith Young; Steven H Bernstein; Derick Peterson; Lynn Rich; Susan Blumel; Nicole K Proia; Jane Liesveld; Richard I Fisher; James O Armitage; Steven Grant; John P Leonard
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Blood 2011;117(10):2807-12.
2011: Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph Michael Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Oncogenically active MYD88 mutations in human lymphoma.
Nature 2011;470(7332):115-9.
2011: Denise M Oliansky; Myron Czuczman; Richard I Fisher; Frank D Irwin; Hillard M Lazarus; James Omel; Julie Vose; Steven Neil Wolff; Roy B Jones; Philip L McCarthy; Theresa Hahn
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2011;17(1):20-47.e30.
2010: Ranjana H Advani; Haiyan Chen; Thomas M Habermann; Vicki A Morrison; Edie A Weller; Richard I Fisher; Bruce A Peterson; Randy D Gascoyne; Sandra J Horning
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
British journal of haematology 2010;151(2):143-51.
2010: André Goy; Steven H Bernstein; Alice McDonald; Michael D Pickard; Hongliang Shi; Mark D Fleming; Bryant Barbara; William Trepicchio; Richard I Fisher; Anthony L Boral; George Mulligan
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.
Leukemia & lymphoma 2010;51(7):1269-77.
2010: Girija Dasmahapatra; Dmitry Lembersky; Lora Kramer; Richard I Fisher; Jonathan Friedberg; Paul Dent; Steven Grant
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Blood 2010;115(22):4478-87.
2010: John W Sweetenham; B Goldman; M L LeBlanc; J R Cook; R R Tubbs; O W Press; D G Maloney; Richard I Fisher; L M Rimsza; Rita M Braziel; Eric D Hsi
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(6):1196-202.
2010: Tithi Biswas; Sughosh Dhakal; Rui Chen; Ollivier Hyrien; Steven Bernstein; Jonathan W Friedberg; Richard I Fisher; Jane L Liesveld; Gordon Phillips; Louis S Constine
Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
International journal of radiation oncology, biology, physics 2010;77(1):79-85.
2010: Jane N Winter; Shuli Li; Vikas Aurora; Daina Variakojis; Beverly Nelson; Maryla Krajewska; Lijun Zhang; Thomas M Habermann; Richard I Fisher; William R Macon; Mukesh Chhanabhai; Raymond E Felgar; Eric D Hsi; L Jeffrey Medeiros; James K Weick; Edie A Weller; Ari Melnick; John C Reed; Sandra J Horning; Randy D Gascoyne
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(8):2435-42.
2010: Tri K Nguyen; Nicholas Jordan; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.
Leukemia research 2010;34(3):379-86.
2010: R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph Michael Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature 2010;463(7277):88-92.
2009: Jennifer L Kelly; Stephen R Toothaker; Lauren Ciminello; Dieter Hoelzer; Harald Holte; Ann S LaCasce; Graham Mead; Deborah Thomas; Gustaaf W van Imhoff; Brad S Kahl; Bruce D Cheson; Ian Trevor Magrath; Richard I Fisher; Jonathan W Friedberg
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
Clinical lymphoma & myeloma 2009;9(4):307-10.
2009: Jonathan W Friedberg; Jennifer L Kelly; Donna Neuberg; Derick R Peterson; Jeffery L Kutok; Rabih Salloum; Thomas Brenn; David C Fisher; Elizabeth Ronan; Virginia Dalton; Lynn Rich; Diana Marquis; Paul Sims; Paul G Rothberg; Jane L Liesveld; Richard I Fisher; Robert Coffman; Tim Mosmann; Arnold S Freedman
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.
British journal of haematology 2009;146(3):282-91.
2009: Jennifer R Brown; Jonathan W Friedberg; Yang Feng; Sarah Scofield; Kimberly Phillips; Paola Dal Cin; Robin Joyce; Ronald W Takvorian; David C Fisher; Richard I Fisher; Jane Liesveld; Diana Marquis; Donna Neuberg; Arnold S Freedman
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
British journal of haematology 2009;145(6):741-8.
2009: Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; William T Bellamy; Maria Iannone; Daniel O Persky; Michael LeBlanc; Richard I Fisher; Thomas P Miller
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.
Leukemia & lymphoma 2009;50(5):728-35.
2009: Girija Dasmahapatra; Dmitry Lembersky; Mohamed Rahmani; Lora Kramer; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
Cancer biology & therapy 2009;8(9):808-19.
2009: Shannon P Hilchey; Ollivier Hyrien; Tim R Mosmann; Alexandra M Livingstone; Jonathan W Friedberg; Faith Young; Richard I Fisher; Raymond J Kelleher; Richard B Bankert; Steven H Bernstein
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.
Blood 2009;113(16):3809-12.
2009: A Goy; S H Bernstein; B S Kahl; Benjamin Djulbegovic; M J Robertson; S de Vos; E Epner; A Krishnan; J P Leonard; Sagar Lonial; S Nasta; O A O'Connor; H Shi; A L Boral; Richard I Fisher
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(3):520-5.
2009: Steven H Bernstein; Joseph M Unger; Michael Leblanc; Jonathan Friedberg; Thomas P Miller; Richard I Fisher
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):114-9.
2008: G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; Joseph Michael Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; Erlend Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; Rita M Braziel; T P Miller; Lisa M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; Richard I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt
Stromal gene signatures in large-B-cell lymphomas.
The New England journal of medicine 2008;359(22):2313-23.
2008: Jonathan W Friedberg; Richard I Fisher
Diffuse large B-cell lymphoma.
Hematology/oncology clinics of North America 2008;22(5):941-52, ix.
2008: J H Mendler; J Kelly; Susan L Voci; D Marquis; L Rich; Randall M Rossi; Steven H Bernstein; Craig T Jordan; Jane L Liesveld; Richard I Fisher; J W Friedberg
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(10):1759-64.
2008: Georg Lenz; George W Wright; N C Tolga Emre; Holger Kohlhammer; Sandeep S Dave; R Eric Davis; Shannon Carty; Lloyd T Lam; A L Shaffer; Wenming Xiao; John Powell; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph Michael Connors; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend Smeland; Lisa M Rimsza; Richard I Fisher; Dennis D Weisenburger; Wing C Chan; Louis M Staudt
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(36):13520-5.
2008: Lode J Swinnen; Michael LeBlanc; Thomas M Grogan; Leo I Gordon; Patrick J Stiff; Alan Marshall Miller; Yvette L Kasamon; Thomas P Miller; Richard I Fisher
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.
Transplantation 2008;86(2):215-22.
2008: Daniel O Persky; Joseph M Unger; Catherine Spier; Baldassarre Stea; Michael LeBlanc; Matthew J McCarty; Lisa M Rimsza; Richard I Fisher; Thomas P Miller
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2258-63.
2008: Alison R Walker; Anatole Kleiner; Lynn Rich; Charlene Conners; Richard I Fisher; Jennifer Anolik; Jonathan W Friedberg
Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.
Cancer investigation 2008;26(4):431-3.
2008: John A Thompson; Richard I Fisher; Michael Leblanc; Stephen J Forman; Oliver W Press; Joseph M Unger; Auayporn P Nademanee; Patrick J Stiff; Stephen H Petersdorf; Alexander Fefer
Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438).
Blood 2008;111(8):4048-54.
2008: Georg Lenz; R Eric Davis; Vu N Ngo; Lloyd Lam; Thaddeus C George; George W Wright; Sandeep Dave; Hong Zhao; Weihong Xu; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph Michael Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend Smeland; Richard I Fisher; Wing C Chan; Louis M Staudt
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
Science (New York, N.Y.) 2008;319(5870):1676-9.
2007: Adrian Wiestner; Mahsa Tehrani; Michael Chiorazzi; George Wright; Federica Gibellini; Kazutaka Nakayama; Hui Liu; Andreas Rosenwald; H Konrad Muller-Hermelink; German Ott; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; Julie M Vose; James O Armitage; Randy D Gascoyne; Joseph Michael Connors; Elias Campo; Emili Montserrat; Francesc Bosch; Erlend Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard I Fisher; Thomas M Grogan; Thomas P Miller; Wyndham H Wilson; Elaine S Jaffe; Louis M Staudt
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.
Blood 2007;109(11):4599-606.
2007: Georg Lenz; Inga Nagel; Reiner Siebert; Anna V Roschke; Warren Sanger; George W Wright; Sandeep S Dave; Bruce Tan; Hong Zhao; Andreas Rosenwald; H Konrad Muller-Hermelink; Randy D Gascoyne; Elias Campo; Elaine S Jaffe; Erlend Smeland; Richard I Fisher; W Michael Kuehl; Wing C Chan; Louis M Staudt
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.
The Journal of experimental medicine 2007;204(3):633-43.
2007: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph Michael Connors; Massimo Federico; Volker Diehl
Revised response criteria for malignant lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):579-86.
2007: Julia Schaefer-Cutillo; Jonathan W Friedberg; Richard I Fisher
Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.
Oncology (Williston Park, N.Y.) 2007;21(2):203-12; discussion 214, 217, 221.
2007: Jennifer H Anolik; Jonathan W Friedberg; Bo Zheng; Jennifer Barnard; Teresa Owen; Emily Cushing; Jennifer Kelly; Eric Milner; Richard I Fisher; Iñaki Sanz
B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.
Clinical immunology (Orlando, Fla.) 2007;122(2):139-45.
2006: Richard I Fisher; Steven H Bernstein; Brad S Kahl; Benjamin Djulbegovic; Michael J Robertson; Sven de Vos; Elliot Epner; Amrita Krishnan; John P Leonard; Sagar Lonial; Edward A Stadtmauer; Owen A O'Connor; Hongliang Shi; Anthony Boral; Andre Goy
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4867-74.
2006: Richard I Fisher
Treatment of diffuse large B-cell lymphomas.
Seminars in hematology 2006;43(4):205-6.
2006: Oliver W Press; Joseph M Unger; Rita M Braziel; David G Maloney; Thomas P Miller; Michael LeBlanc; Richard I Fisher
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(25):4143-9.
2006: Susan G Fisher; Richard I Fisher
The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications.
Current opinion in oncology 2006;18(5):417-24.
2006: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3121-7.
2006: Sandeep S Dave; Kai Fu; George W Wright; Lloyd T Lam; Philip Kluin; Evert-Jan Boerma; Timothy C Greiner; Dennis D Weisenburger; Andreas Rosenwald; German Ott; Hans-Konrad Müller-Hermelink; Randy D Gascoyne; Jan Delabie; Lisa M Rimsza; Rita M Braziel; Thomas M Grogan; Elias Campo; Elaine S Jaffe; Bhavana J Dave; Warren Sanger; Martin Bast; Julie M Vose; James O Armitage; Joseph Michael Connors; Erlend Smeland; Stein Kvaloy; Harald Holte; Richard I Fisher; Thomas P Miller; Emilio Montserrat; Wyndham H Wilson; Manisha Bahl; Hong Zhao; Liming Yang; John Powell; Richard Simon; Wing C Chan; Louis M Staudt
Molecular diagnosis of Burkitt's lymphoma.
The New England journal of medicine 2006;354(23):2431-42.
2006: Rami S Komrokji; Nikhil P Uppal; Alok A Khorana; Gary H Lyman; Karen L Kaplan; Richard I Fisher; Charles W Francis
Venous thromboembolism in patients with diffuse large B-cell lymphoma.
Leukemia & lymphoma 2006;47(6):1029-33.
2006: Jane N Winter; Edie A Weller; Sandra J Horning; Maryla Krajewska; Daina Variakojis; Thomas M Habermann; Richard I Fisher; Paul J Kurtin; William R Macon; Mukesh Chhanabhai; Raymond E Felgar; Eric D Hsi; L Jeffrey Medeiros; James K Weick; John C Reed; Randy D Gascoyne
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Blood 2006;107(11):4207-13.
2006: Richard I Fisher; Bertrand Coiffier; Julie M Vose
Advances in the treatment of hematologic malignancies. Part 1 of a 3-part series: Aggressive lymphomas.
Clinical advances in hematology & oncology : H&O 2006;4(4):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10.
2006: Lisa M Rimsza; Robin A Roberts; Elias Campo; Thomas M Grogan; Silvia Bea; Itziar Salaverria; Andreas Zettl; Andreas Rosenwald; German Ott; H Konrad Muller-Hermelink; Jan Delabie; Richard I Fisher; Joseph M Unger; Michael LeBlanc; Louis M Staudt; Elaine S Jaffe; Randy D Gascoyne; Wing C Chan; Dennis D Weisenburger; Timothy Greiner; Rita M Braziel; Thomas P Miller
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.
Blood 2006;107(3):1101-7.
2006: Alok A Khorana; Charles W Francis; Eva Culakova; Richard I Fisher; Nicole Kuderer; Gary H Lyman
Thromboembolism in hospitalized neutropenic cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):484-90.
2006: Jonathan W Friedberg; Richard I Fisher
Diffuse large B-cell NHL.
Cancer treatment and research 2006;131():121-40.
2005: Richard I Fisher; Michael LeBlanc; Oliver W Press; David G Maloney; Joseph M Unger; Thomas P Miller
New treatment options have changed the survival of patients with follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(33):8447-52.
2005: Julie M Vose; B K Link; M L Grossbard; Myron S Czuczman; A Grillo-Lopez; Richard I Fisher
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Leukemia & lymphoma 2005;46(11):1569-73.
2005: Silvia Bea; Andreas Zettl; George Wright; Itziar Salaverria; Philipp Jehn; Victor Moreno; Christof Burek; German Ott; Xavier Puig; Liming Yang; Armando Lopez-Guillermo; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; James O Armitage; Randy D Gascoyne; Joseph Michael Connors; Thomas M Grogan; Rita M Braziel; Richard I Fisher; Erlend Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard Simon; John Powell; Wyndham H Wilson; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Elias Campo; Andreas Rosenwald
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.
Blood 2005;106(9):3183-90.
2005: Richard I Fisher; Mark S Kaminski; Richard L Wahl; Susan J Knox; Andrew D Zelenetz; Julie M Vose; John P Leonard; Stewart Kroll; Stanley J Goldsmith; Morton Coleman
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7565-73.
2005: Richard I Fisher
Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL.
Clinical advances in hematology & oncology : H&O 2005;3(7):544-6.
2005: Richard I Fisher
Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma.
Clinical advances in hematology & oncology : H&O 2005;3(7):544-6.
2005: Lynda Song; Andrei Zlobin; Pushpankur Ghoshal; Qing Zhang; Christiane Houde; Sanne Weijzen; Qun Jiang; Elizabeth Nacheva; Danny Yagan; Eric Davis; Sylvie Galiegue-Zouitina; Daniel Catovsky; Thomas M Grogan; Richard I Fisher; Lucio Miele; Lionel J Coignet
Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas.
Cancer research 2005;65(11):4554-61.
2005: Ama Z S Rohatiner; Walter Gregory; B Peterson; Ernest C Borden; Philippe Solal-Celigny; Anton Hagenbeek; Richard I Fisher; Michael Unterhalt; R Arranz; T Chisesi; A Aviles; T Andrew Lister
Meta-analysis to evaluate the role of interferon in follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2215-23.
2005: Richard I Fisher
Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):657-8.
2004: Sandeep S Dave; George Wright; Bruce Tan; Andreas Rosenwald; Randy D Gascoyne; Wing C Chan; Richard I Fisher; Rita M Braziel; Lisa M Rimsza; Thomas M Grogan; Thomas P Miller; Michael LeBlanc; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Joseph Michael Connors; Peter M Lansdorp; Qin Ouyang; T Andrew Lister; Andrew J Davies; Andrew J Norton; H Konrad Muller-Hermelink; German Ott; Elias Campo; Emilio Montserrat; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Liming Yang; John Powell; Hong Zhao; Neta Goldschmidt; Michael Chiorazzi; Louis M Staudt
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
The New England journal of medicine 2004;351(21):2159-69.
2004: Gary H Lyman; David C Dale; Jonathan W Friedberg; Jeffrey Crawford; Richard I Fisher
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(21):4302-11.
2004: Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; cesare guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Follicular lymphoma international prognostic index.
Blood 2004;104(5):1258-65.
2004: Susan G Fisher; Richard I Fisher
The epidemiology of non-Hodgkin's lymphoma.
Oncogene 2004;23(38):6524-34.
2004: Lisa M Rimsza; Robin A Roberts; Thomas P Miller; Joseph M Unger; Michael LeBlanc; Rita M Braziel; Dennis D Weisenberger; Wing C Chan; H Konrad Muller-Hermelink; Elaine S Jaffe; Randy D Gascoyne; Elias Campo; Deborah A Fuchs; Catherine Spier; Richard I Fisher; Jan Delabie; Andreas Rosenwald; Louis M Staudt; Thomas M Grogan
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.
Blood 2004;103(11):4251-8.
2004: Jonathan W Friedberg; Richard I Fisher
Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
Expert review of anticancer therapy 2004;4(1):18-26.
2004: Richard I Fisher; Thomas P Miller; Owen A O'Connor
Diffuse aggressive lymphoma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2004;():221-36.
2003: Theresa Hahn; Steven Neil Wolff; Myron S Czuczman; Richard I Fisher; Hillard M Lazarus; Philip L McCarthy; Julie M Vose; Lisa Warren; Richard Watt
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2003;9(10):667.
2003: Richard I Fisher; P Shah
Current trends in large cell lymphoma.
Leukemia 2003;17(10):1948-60.
2003: Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph Michael Connors; Rita M Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.
The Journal of experimental medicine 2003;198(6):851-62.
2003: Patricia Anne Ganz; Carol M Moinpour; Donna K Pauler; Alice B Kornblith; Ellen R Gaynor; Stanley P Balcerzak; Gretchen S Gatti; Harry P Erba; Sheryl McCoy; Oliver W Press; Richard I Fisher
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(18):3512-9.
2003: Oliver W Press; Joseph M Unger; Rita M Braziel; David G Maloney; Thomas P Miller; Michael LeBlanc; Ellen R Gaynor; Saul E Rivkin; Richard I Fisher
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
Blood 2003;102(5):1606-12.
2003: Patrick J Stiff; Joseph M Unger; Stephen J Forman; Anne R McCall; Michael LeBlanc; Auayporn Nademanee; Brian J Bolwell; Richard I Fisher
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2003;9(8):529-39.
2003: Douglas W Blayney; Michael L LeBlanc; Thomas M Grogan; Ellen R Gaynor; Robert A Chapman; C Harris Spiridonidis; Sarah A Taylor; Scott I Bearman; Thomas P Miller; Richard I Fisher
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2466-73.
2003: William S Velasquez; Danika Lew; Thomas M Grogan; C Harris Spiridonidis; Stanley P Balcerzak; Shaker R Dakhil; Thomas P Miller; Keith S Lanier; Robert A Chapman; Richard I Fisher
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10):1996-2003.
2003: Richard I Fisher
Overview of non-Hodgkin's lymphoma: biology, staging, and treatment.
Seminars in oncology 2003;30(2 Suppl 4):3-9.
2003: David B Duggan; Gina R Petroni; Jeffrey L Johnson; John Glick; Richard I Fisher; Joseph Michael Connors; George P Canellos; Bruce A Peterson
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):607-14.
2003: Andreas Rosenwald; George Wright; Adrian Wiestner; Wing C Chan; Joseph Michael Connors; Elias Campo; Randy D Gascoyne; Thomas M Grogan; H Konrad Muller-Hermelink; Erlend Smeland; Michael Chiorazzi; Jennifer Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Sarah Henrickson; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Emilio Montserrat; Francesc Bosch; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Richard I Fisher; Thomas P Miller; Michael LeBlanc; German Ott; Stein Kvaloy; Harald Holte; Jan Delabie; Louis M Staudt
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.
Cancer cell 2003;3(2):185-97.
2002: Richard I Fisher
Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(22):4411-2.
2002: Andreas Rosenwald; George Wright; Wing C Chan; Joseph Michael Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend Smeland; Jennifer Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
The New England journal of medicine 2002;346(25):1937-47.
2001: J E Godwin; Richard I Fisher
Diffuse large-cell lymphomas: a review of therapy.
Clinical lymphoma 2001;2(3):155-63.
2001: Oliver W Press; Michael LeBlanc; A S Lichter; Thomas M Grogan; Joseph M Unger; Todd H Wasserman; Ellen R Gaynor; Bruce A Peterson; Thomas P Miller; Richard I Fisher
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(22):4238-44.
2001: Richard I Fisher
Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1835-6.
2001: Lawrence E Flaherty; Michael Atkins; Jeffrey A Sosman; G Weiss; JI Clark; Kim Margolin; Janice Dutcher; Michael S Gordon; Michael Lotze; James W Mier; Patricia Sorokin; Richard I Fisher; C Appel; Wei Du
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3194-202.
2001: Rita M Braziel; D A Arber; Marilyn L Slovak; Margaret L Gulley; Catherine Spier; CR Kjeldsberg; J Unger; Thomas P Miller; R Tubbs; CP Leith; Richard I Fisher; Thomas M Grogan
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features.
Blood 2001;97(12):3713-20.
2001: Ellen R Gaynor; Joseph M Unger; Thomas P Miller; Thomas M Grogan; L A White; Glenn M Mills; Stanley P Balcerzak; M Varterasian; Michael LeBlanc; Richard I Fisher
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):750-5.
2001: Julie M Vose; B K Link; M L Grossbard; Myron S Czuczman; A Grillo-Lopez; P Gilman; A Lowe; L A Kunkel; Richard I Fisher
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):389-97.
2001: Richard I Fisher
Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining.
Journal of the National Cancer Institute 2001;93(1):4-5.
2001: Theresa Hahn; Steven Neil Wolff; Myron S Czuczman; Richard I Fisher; Hillard M Lazarus; Julie M Vose; L Warren; R Watt; Philip L McCarthy
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2001;7(6):308-31.
2000: Richard I Fisher
Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma.
Seminars in oncology 2000;27(6 Suppl 12):2-8.
2000: C W Taylor; M LeBlanc; Richard I Fisher; D F Moore; R W Roach; L Elias; Thomas P Miller
Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial.
Anti-cancer drugs 2000;11(9):695-700.
2000: Richard I Fisher; B W Dana; Michael LeBlanc; CR Kjeldsberg; Jeffrey D Forman; Joseph M Unger; Stanley P Balcerzak; Ellen R Gaynor; V Roy; T Miller
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(10):2010-6.
2000: Richard I Fisher; STEVEN ROSENBERG; G Fyfe
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
The cancer journal from Scientific American 2000;6 Suppl 1():S55-7.
2000: Richard I Fisher
Diffuse large-cell lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 1():29-33.
1999: Paola Rizzo; Michele Carbone; Susan G Fisher; CM Matker; LJ Swinnen; Amy Powers; I Di Resta; Serhan Alkan; Harvey I Pass; Richard I Fisher
Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma.
Chest 1999;116(6 Suppl):470S-473S.
1999: Michael B Atkins; M T Lotze; Janice P Dutcher; Richard I Fisher; G Weiss; K Margolin; Jeffrey Abrams; Mario Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; STEVEN ROSENBERG
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2105-16.
1999: Bruce D Cheson; Sandra J Horning; Bertrand Coiffier; Margaret A Shipp; Richard I Fisher; J M Connors; T A Lister; Julie M Vose; Antonio J Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; James O Armitage; W Carter; R Hoppe; George P Canellos
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1244.
1999: D F Moore; T D Brown; M LeBlanc; Seth Dahlberg; Thomas P Miller; S McClure; Richard I Fisher
Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial.
Investigational new drugs 1999;17(2):169-72.
1998: Robert Peter Gale; RE Park; R Dubois; P J Bierman; Richard I Fisher; K K Loh; Bruce A Peterson; Gordon L Phillips; Carol S Portlock; D Rosenblum; J O Armitage
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma.
Leukemia & lymphoma 1998;32(1-2):139-49.
1998: Thomas P Miller; Seth Dahlberg; J R Cassady; D J Adelstein; Catherine Spier; Thomas M Grogan; Michael LeBlanc; S Carlin; E Chase; Richard I Fisher
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
The New England journal of medicine 1998;339(1):21-6.
1998: Richard I Fisher; Thomas P Miller; Thomas M Grogan
New REAL clinical entities.
The cancer journal from Scientific American 1998;4 Suppl 2():S5-12.
1998: Richard I Fisher
Relapse after successful treatment with immunotherapy: lessons for the future.
The cancer journal from Scientific American 1998;4(2):78-9.
1998: Markus Loeffler; Oana Brosteanu; Dirk Hasenclever; Michael Sextro; D Assouline; Alfred A Bartolucci; Peter A Cassileth; D Crowther; Volker Diehl; Richard I Fisher; R T Hoppe; P Jacobs; J L Pater; S Pavlovsky; E Thompson; Peter H Wiernik
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):818-29.
1998: Jane N Winter; J Andersen; J C Reed; S Krajewski; Daina Variakojis; K D Bauer; Richard I Fisher; Leo I Gordon; Martin M Oken; S Jiang; D Jeffries; P Domer
BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study.
Blood 1998;91(4):1391-8.
1998: Oliver W Press; M LeBlanc; T J O'Rourke; S Gagnet; Robert A Chapman; Stanley P Balcerzak; Richard I Fisher
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):574-8.
1998: Richard I Fisher
Treatment of grey zone lymphomas.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S121-3.
1998: Ellen R Gaynor; Richard I Fisher
CHOP therapy: has shorter-course therapy had an impact on lymphomas?
Cancer investigation 1998;16(1):26-32.
1998: Patrick J Stiff; Seth Dahlberg; S J Forman; A R McCall; S J Horning; Auayporn Nademanee; Karl G Blume; Michael LeBlanc; Richard I Fisher
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):48-55.
1998: John Glick; M L Young; D Harrington; R L Schilsky; T Beck; R Neiman; Richard I Fisher; Bruce A Peterson; Martin M Oken
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):19-26.
1997: Janice P Dutcher; M Atkins; Richard I Fisher; G Weiss; K Margolin; Frederick R Aronson; Jeffrey A Sosman; Michael Lotze; Michael Gordon; Theodore Logan; James W Mier
Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
The cancer journal from Scientific American 1997;3 Suppl 1():S73-8.
1997: Richard I Fisher; STEVEN ROSENBERG; Mario Sznol; D R Parkinson; G Fyfe
High-dose aldesleukin in renal cell carcinoma: long-term survival update.
The cancer journal from Scientific American 1997;3 Suppl 1():S70-2.
1997: Thomas P Miller; Michael LeBlanc; Thomas M Grogan; Richard I Fisher
Follicular lymphomas: do histologic subtypes predict outcome?
Hematology/oncology clinics of North America 1997;11(5):893-900.
1997: Thomas M Grogan; Thomas P Miller; Richard I Fisher
A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification.
Hematology/oncology clinics of North America 1997;11(5):819-46.
1997: Janice P Dutcher; Richard I Fisher; G Weiss; Frederick R Aronson; K Margolin; A Louie; James W Mier; G Caliendo; Jeffrey A Sosman; J R Eckardt; M L Ernest; James Doroshow; M Atkins
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
The cancer journal from Scientific American 1997;3(3):157-62.
1997: Kim Margolin; Michael Atkins; Joseph A Sparano; Jeffrey A Sosman; G Weiss; Michael Lotze; James Doroshow; James W Mier; K O'Boyle; Richard I Fisher; E Campbell; Joshua Rubin; D Federighi; SL Bursten
Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(4):565-72.
1997: Jeffrey A Sosman; Frederick R Aronson; Mario Sznol; Michael B Atkins; Janice P Dutcher; Geoffrey R Weiss; R E Isaacs; Kim Margolin; Richard I Fisher; M L Ernest; James W Mier; L Oleksowicz; J R Eckhardt; D Levitt; James Doroshow
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(1):39-46.
1997: Richard I Fisher
Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.
Cancer chemotherapy and pharmacology 1997;40 Suppl():S42-6.
1996: Wolfgang Hiddemann; Dan Longo; Bertrand Coiffier; Richard I Fisher; F Cabanillas; F Cavalli; Lee M Nadler; V T De Vita; T A Lister; J O Armitage
Lymphoma classification--the gap between biology and clinical management is closing.
Blood 1996;88(11):4085-9.
1996: J N Winter; J Andersen; Daina Variakojis; Leo I Gordon; Richard I Fisher; M M Oken; R S Neiman; S Jiang; K D Bauer
Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
Blood 1996;88(10):3919-25.
1996: G A Fyfe; Richard I Fisher; S A Rosenberg; Mario Sznol; D R Parkinson; A C Louie
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(8):2410-1.
1996: Richard I Fisher
Mantle-cell lymphoma: classification and therapeutic implications.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 6():S35-9.
1996: Richard I Fisher
Report of workshop 5: early high-dose chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 4():131-3.
1995: Ellen R Gaynor; Richard I Fisher
Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better?
Oncology (Williston Park, N.Y.) 1995;9(12):1273-9; discussion 1283-4.
1995: LJ Swinnen; G Martin Mullen; T J Carr; Maria Rosa Costanzo; Richard I Fisher
Aggressive treatment for postcardiac transplant lymphoproliferation.
Blood 1995;86(9):3333-40.
1995: Jeffrey A Sosman; K Bartemes; K P Offord; H Kita; Susan G Fisher; C Kefer; T A Ellis; Richard I Fisher; T J Higgins; G J Gleich
Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(8):805-12.
1995: Jeffrey A Sosman; C Kefer; Richard I Fisher; C D Jacobs; P Pumfery; T M Ellis
A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(3):171-80.
1995: G Fyfe; Richard I Fisher; S A Rosenberg; Mario Sznol; D R Parkinson; A C Louie
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):688-96.
1995: Richard I Fisher; S Dahlberg; B N Nathwani; P M Banks; T P Miller; T M Grogan
A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.
Blood 1995;85(4):1075-82.
1995: M Alzona; Hans-Martin Jäck; Richard I Fisher; T M Ellis
IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(1):9-16.
1995: Richard I Fisher; M M Oken
Clinical practice guidelines: non-Hodgkin's lymphomas.
Cleveland Clinic journal of medicine 1995;62 Suppl 1():SI6-42, quiz SI43-5.
1994: J Hamm; J H Schiller; C Cuffie; M Oken; Richard I Fisher; F Shepherd; G Kaiser
Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2667-76.
1994: Richard I Fisher
Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years.
Cancer 1994;74(9 Suppl):2657-61.
1994: M Alzona; Hans-Martin Jäck; Richard I Fisher; T M Ellis
CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(7):2861-7.
1994: Joseph A Sparano; Richard I Fisher; G R Weiss; Kim Margolin; Frederick R Aronson; M J Hawkins; Michael B Atkins; Janice P Dutcher; E R Gaynor; D H Boldt
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):216-23.
1994: Dan Longo; P L Duffey; Elaine S Jaffe; Mark Raffeld; S M Hubbard; Richard I Fisher; Robert Wittes; V T DeVita; R C Young
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2153-9.
1994: Michael B Atkins; K R O'Boyle; Jeffrey A Sosman; G R Weiss; Kim Margolin; M L Ernest; K Kappler; James W Mier; Joseph A Sparano; Richard I Fisher
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(8):1553-60.
1994: C J Fabian; Carl M Mansfield; S Dahlberg; S E Jones; T P Miller; E Van Slyck; P N Grozea; F S Morrison; C A Coltman; Richard I Fisher
Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study.
Annals of internal medicine 1994;120(11):903-12.
1994: Jeffrey A Sosman; Susan G Fisher; C Kefer; Richard I Fisher; T M Ellis
A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(5):447-52.
1994: R Saez; S Dahlberg; F R Appelbaum; R J Hartsock; F Lemaistre; C A Coltman; Richard I Fisher
Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study.
Hematological oncology 1994;12(2):75-85.
1994: Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; Rasim Gucalp; Richard I Fisher; M Sunderland; James Doroshow; M L Ernest; James W Mier
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(2):147-53.
1994: Sucha Nand; Jeffrey A Sosman; J E Godwin; Richard I Fisher
A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes.
Blood 1994;83(2):357-60.
1994: M J Hawkins; Michael B Atkins; Janice P Dutcher; Richard I Fisher; G R Weiss; Kim Margolin; A A Rayner; Mario Sznol; D R Parkinson; Elisabeth Paietta
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(1):74-8.
1994: Richard I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 2():91-5.
1993: Joseph A Sparano; Richard I Fisher; M Sunderland; Kim Margolin; M L Ernest; Mario Sznol; Michael B Atkins; Janice P Dutcher; K C Micetich; G R Weiss
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):1969-77.
1993: T M Ellis; P E Simms; D J Slivnick; Hans-Martin Jäck; Richard I Fisher
CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(5):2380-9.
1993: Jeffrey A Sosman; G R Weiss; Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; K O'Boyle; Richard I Fisher; D H Boldt; James Doroshow
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1496-505.
1993: LJ Swinnen; Richard I Fisher
OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation.
Current opinion in nephrology and hypertension 1993;2(4):670-8.
1993: Richard I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
The New England journal of medicine 1993;328(14):1002-6.
1993: Michael B Atkins; Joseph A Sparano; Richard I Fisher; G R Weiss; Kim Margolin; K I Fink; L Rubinstein; A Louie; James W Mier; Rasim Gucalp
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(4):661-70.
1993: B W Dana; S Dahlberg; B N Nathwani; E Chase; C Coltman; Thomas P Miller; Richard I Fisher
Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(4):644-51.
1993: E Poplin; T Fleming; J S MacDonald; P Eisenberg; Richard I Fisher; M E Conrad
Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study.
Investigational new drugs 1993;11(1):47-51.
1992: R S McKenzie; P E Simms; B A Helfrich; Richard I Fisher; T M Ellis
Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
Cancer research 1992;52(22):6318-22.
1992: H T Maecker; D M Jokinen; Richard I Fisher
T cell receptor expression can switch on and off at a posttranslational level.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(5):1619-25.
1992: Kathy S Albain; LJ Swinnen; L C Erickson; P J Stiff; Susan G Fisher; Richard I Fisher
Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience.
Seminars in oncology 1992;19(3 Suppl 9):102-9.
1992: R A Bayer; E R Gaynor; Richard I Fisher
Bleomycin in non-Hodgkin's lymphoma.
Seminars in oncology 1992;19(2 Suppl 5):46-52; discussion 52-3.
1992: Sucha Nand; T Ellis; Harry L Messmore; Susan G Fisher; E Gaynor; Richard I Fisher
Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.
Leukemia 1992;6(3):220-3.
1992: K C Micetich; Bernard W Futscher; D Koch; Richard I Fisher; L C Erickson
Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer.
Journal of the National Cancer Institute 1992;84(4):256-60.
1991: E R Gaynor; Richard I Fisher
Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma.
Seminars in oncology 1991;18(5 Suppl 7):12-7.
1991: E R Gaynor; Richard I Fisher
Chemotherapy and combined modality treatment in Hodgkin's disease.
Current opinion in oncology 1991;3(5):822-9.
1991: Thomas P Miller; S Dahlberg; Sydney E Salmon; S K Williamson; R J Belt; B W Dana; Richard I Fisher
Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1204-9.
1991: Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; N Ciobanu; Richard I Fisher; G R Weiss; James Doroshow; M H Bar; M J Hawkins
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(3):214-20.
1991: S Dahlberg; T P Miller; Richard I Fisher
A clinical phase II study of ProMACE-CytaBOM.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(5):888.
1991: J K Weick; S Dahlberg; Richard I Fisher; B Dana; Thomas P Miller; Stanley P Balcerzak; H I Pierce
Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(5):748-53.
1991: Janice P Dutcher; E R Gaynor; D H Boldt; James Doroshow; M H Bar; Mario Sznol; James W Mier; Joseph A Sparano; Richard I Fisher; G Weiss
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(4):641-8.
1991: Clive Landis; M L Friedman; Richard I Fisher; T M Ellis
Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(1):128-35.
1991: Richard I Fisher; Dan Longo; V T DeVita; S M Hubbard; T P Miller; R C Young
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2 Suppl 1():33-5.
1991: Dan Longo; V T DeVita; P L Duffey; M N Wesley; D C Ihde; S M Hubbard; M Gilliom; Elaine S Jaffe; J Cossman; Richard I Fisher
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(1):25-38.
1990: LJ Swinnen; M R Costanzo-Nordin; Susan G Fisher; E J O'Sullivan; MR Johnson; Alain Heroux; G J Dizikes; R Pifarre; Richard I Fisher
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.
The New England journal of medicine 1990;323(25):1723-8.
1990: D J Slivnick; T M Ellis; J F Nawrocki; Richard I Fisher
The impact of Hodgkin's disease on the immune system.
Seminars in oncology 1990;17(6):673-82.
1990: T P Miller; S Dahlberg; J K Weick; J C Files; H J Eyre; K B Pendergrass; Richard I Fisher
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(12):1951-8.
1990: D R Parkinson; Richard I Fisher; A A Rayner; Elisabeth Paietta; Kim Margolin; G R Weiss; James W Mier; Mario Sznol; E R Gaynor; M H Bar
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1630-6.
1990: E R Gaynor; G R Weiss; Kim Margolin; Frederick R Aronson; Mario Sznol; P Demchak; K M Grima; Richard I Fisher; D H Boldt; James Doroshow
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
Journal of the National Cancer Institute 1990;82(17):1397-402.
1990: P A Sobotka; J McMannis; Richard I Fisher; D G Stein; J X Thomas
Effects of interleukin 2 on cardiac function in the isolated rat heart.
The Journal of clinical investigation 1990;86(3):845-50.
1990: B W Dana; S Dahlberg; Thomas P Miller; R J Hartsock; Stanley P Balcerzak; C A Coltman; J O Carden; K Hartley; Richard I Fisher
m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1155-62.
1990: Sucha Nand; Harry L Messmore; Susan G Fisher; M L Bird; W Schulz; Richard I Fisher
Leukemic transformation in polycythemia vera: analysis of risk factors.
American journal of hematology 1990;34(1):32-6.
1990: I B Weisfuse; D J Graham; M Will; D Parkinson; David R Snydman; M Atkins; Ruth A Karron; Stephen M Feinstone; A A Rayner; Richard I Fisher
An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells.
The Journal of infectious diseases 1990;161(4):647-52.
1990: Richard I Fisher; P J Stiff
Treatment options for recurrent lymphomas.
Seminars in oncology 1990;17(2 Suppl 4):63-7.
1990: Kathy S Albain; LJ Swinnen; L C Erickson; P J Stiff; Richard I Fisher
Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.
Cancer chemotherapy and pharmacology 1990;27(1):33-40.
1990: Richard I Fisher
CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Important advances in oncology 1990;():217-25.
1989: T M Ellis; R S McKenzie; P E Simms; B A Helfrich; Richard I Fisher
Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(12):4282-6.
1989: Dan Longo; E Glatstein; P L Duffey; D C Ihde; S M Hubbard; Richard I Fisher; Elaine S Jaffe; M Gilliom; R C Young; V T DeVita
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(9):1295-302.
1989: E R Gaynor; Richard I Fisher
Recent advances in the management of non-Hodgkin's lymphomas.
Disease-a-month : DM 1989;35(9):597-650.
1989: Richard I Fisher
Picking winners and losers in diffuse small-cell lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(8):991-2.
1989: D J Slivnick; J F Nawrocki; Richard I Fisher
Immunology and cellular biology of Hodgkin's disease.
Hematology/oncology clinics of North America 1989;3(2):205-20.
1989: T M Ellis; Richard I Fisher
Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(8):2949-54.
1989: Kim Margolin; A A Rayner; M J Hawkins; Michael B Atkins; Janice P Dutcher; Richard I Fisher; G R Weiss; James Doroshow; HS Jaffe; M Roper
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(4):486-98.
1989: Janice P Dutcher; S Creekmore; G R Weiss; Kim Margolin; A B Markowitz; M Roper; D Parkinson; N Ciobanu; Richard I Fisher; D H Boldt
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(4):477-85.
1989: LJ Swinnen; D M Barnes; Susan G Fisher; Kathy S Albain; Richard I Fisher; L C Erickson
1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.
Cancer research 1989;49(6):1383-9.
1989: Stephen Creekmore; J E Harris; T M Ellis; D P Braun; I I Cohen; N Bhoopalam; P F Jassak; M A Cahill; C L Canzoneri; Richard I Fisher
A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(2):276-84.
1989: Bernard W Futscher; K C Micetich; D M Barnes; Richard I Fisher; L C Erickson
Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells.
Cancer communications 1989;1(1):65-73.
1988: E R Gaynor; L Vitek; L Sticklin; Stephen Creekmore; M E Ferraro; J X Thomas; S G Fisher; Richard I Fisher
The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells.
Annals of internal medicine 1988;109(12):953-8.
1988: T M Ellis; Stephen Creekmore; J D McMannis; D P Braun; J A Harris; Richard I Fisher
Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.
Cancer research 1988;48(22):6597-602.
1988: T M Ellis; J D McMannis; A O Chua; U Gubler; Richard I Fisher
Interleukin-1-independent activation of human T lymphocytes stimulated by anti-CD3 and a Hodgkin's disease cell line with accessory cell activity.
Cellular immunology 1988;116(2):352-66.
1988: J F Nawrocki; E S Kirsten; Richard I Fisher
Biochemical and structural properties of a Hodgkin's disease-related membrane protein.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(2):672-80.
1988: G A Kozeny; J D Nicolas; S Creekmore; L Sticklin; J E Hano; Richard I Fisher
Effects of interleukin-2 immunotherapy on renal function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(7):1170-6.
1988: Richard I Fisher; C A Coltman; James Doroshow; A A Rayner; M J Hawkins; James W Mier; P Wiernik; J D McMannis; G R Weiss; Kim Margolin
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
Annals of internal medicine 1988;108(4):518-23.
1988: Thomas P Miller; B W Dana; J K Weick; S E Jones; C A Coltman; S Dahlberg; Richard I Fisher
Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Seminars in hematology 1988;25(2 Suppl 2):17-22.
1988: J D McMannis; Richard I Fisher; Stephen Creekmore; D P Braun; J E Harris; T M Ellis
In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(4):1335-40.
1987: Sucha Nand; Susan G Fisher; Ravi Salgia; Richard I Fisher
Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(12):1998-2003.
1987: Patrick J Stiff; A R Koester; M K Weidner; K Dvorak; Richard I Fisher
Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing.
Blood 1987;70(4):974-8.
1987: Richard I Fisher; Thomas P Miller; B W Dana; S E Jones; S Dahlberg; C A Coltman
Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Seminars in hematology 1987;24(2 Suppl 1):21-5.
1986: S Nand; H L Messmore; R Patel; S G Fisher; Richard I Fisher
Neurotoxicity associated with systemic high-dose cytosine arabinoside.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(4):571-5.
1986: M J Browne; S M Hubbard; Dan Longo; Richard I Fisher; R Wesley; D C Ihde; R C Young; P A Pizzo
Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy.
Annals of internal medicine 1986;104(3):338-44.
1986: H Nagai; Richard I Fisher; J Cossman; J J Oppenheim
Decreased expression of class II major histocompatibility antigens on monocytes from patients with Hodgkin's disease.
Journal of leukocyte biology 1986;39(3):313-21.
1985: Richard I Fisher; J Cossman; V Diehl; D J Volkman
Antigen presentation by Hodgkin's disease cells.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(5):3568-71.
1985: Ralph V Boccia; Dan Longo; M L Lieber; E S Jaffe; Richard I Fisher
Multiple recurrences of acute tumor lysis syndrome in an indolent non-Hodgkin's lymphoma.
Cancer 1985;56(9):2295-7.
1985: T T Hecht; Dan Longo; J Cossman; J B Bolen; S M Hsu; M Israel; Richard I Fisher
Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(6):4231-6.
1985: D B Geffen; Richard I Fisher; Dan Longo; R C Young; V T DeVita
Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(5):646-53.
1985: Richard I Fisher; R C Young; Dan Longo; V T DeVita
ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Seminars in oncology 1985;12(1 Suppl 2):29-32.
1984: B A Silver; F W Bostick-Bruton; L Neckers; Richard I Fisher
Deficient helper cell function as a cause of diminished pokeweed mitogen blastogenic responses in patients with non-Hodgkin's lymphomas.
Cancer 1984;54(12):2936-42.
1984: J Cossman; E S Jaffe; Richard I Fisher
Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas. Correlation with clinical features.
Cancer 1984;54(7):1310-7.
1984: Richard I Fisher; S E Bates; F Bostick-Bruton; N Tuteja; V Diehl
Neoplastic cells obtained from Hodgkin's disease function as accessory cells for mitogen-induced human T cell proliferative responses.
Journal of immunology (Baltimore, Md. : 1950) 1984;132(5):2672-7.
1984: Dan Longo; R C Young; S M Hubbard; M Wesley; Richard I Fisher; E Jaffe; C Berard; V T DeVita
Prolonged initial remission in patients with nodular mixed lymphoma.
Annals of internal medicine 1984;100(5):651-6.
1984: S E Shackney; Alexandra M Levine; Richard I Fisher; P Nichols; E Jaffe; W H Schuette; R Simon; C A Smith; S J Occhipinti; J W Parker
The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 cases.
The Journal of clinical investigation 1984;73(4):1201-14.
1983: J Cossman; T M Chused; Richard I Fisher; I Magrath; F Bollum; E S Jaffe
Diversity of immunological phenotypes of lymphoblastic lymphoma.
Cancer research 1983;43(9):4486-90.
1983: Douglas W Blayney; William A Blattner; M Robert-Guroff; E S Jaffe; Richard I Fisher; P A Bunn; M G Patton; H R Rarick; Robert C Gallo
The human T-cell leukemia-lymphoma virus in the southeastern United States.
JAMA : the journal of the American Medical Association 1983;250(8):1048-52.
1983: Robert C Gallo; V S Kalyanaraman; M G Sarngadharan; A Sliski; Eric Vonderheid; M Maeda; Y Nakao; K Yamada; Y Ito; N Gutensohn; S Murphy; P A Bunn; D Catovsky; M F Greaves; Douglas W Blayney; William A Blattner; W F Jarrett; Harald zur Hausen; M Seligmann; J C Brouet; B F Haynes; B V Jegasothy; E Jaffe; J Cossman; S Broder; Richard I Fisher; D W Golde; M Robert-Guroff
Association of the human type C retrovirus with a subset of adult T-cell cancers.
Cancer research 1983;43(8):3892-9.
1983: Richard I Fisher; F Bostick-Bruton; D N Sauder; G Scala; V Diehl
Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures.
Journal of immunology (Baltimore, Md. : 1950) 1983;130(6):2666-70.
1983: Richard I Fisher
Non-Hodgkin's lymphomas after treatment of Hodgkin's disease.
Archives of internal medicine 1983;143(3):427.
1983: Richard I Fisher; V T DeVita; S M Hubbard; Dan Longo; R Wesley; B A Chabner; R C Young
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Annals of internal medicine 1983;98(3):304-9.
1983: Douglas W Blayney; E S Jaffe; Richard I Fisher; G P Schechter; J Cossman; M Robert-Guroff; V S Kalyanaraman; William A Blattner; Robert C Gallo
The human T-cell leukemia/lymphoma virus, lymphoma, lytic bone lesions, and hypercalcemia.
Annals of internal medicine 1983;98(2):144-51.
1982: J L Thomas; M E Bernardino; M Vermess; P A Barnes; L M Fuller; F B Hagemeister; J Doppman; Richard I Fisher; Dan Longo
EOE-13 in the detection of hepatosplenic lymphoma.
Radiology 1982;145(3):629-34.
1982: Richard I Fisher; F Bostick-Bruton
Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide.
Journal of immunology (Baltimore, Md. : 1950) 1982;129(4):1770-4.
1982: Richard I Fisher; B A Silver; C P Vanhaelen; E S Jaffe; J Cossman
Objective regressions of T- and B-cell lymphomas in patients following treatment with anti-thymocyte globulin.
Cancer research 1982;42(6):2465-9.
1982: M Vermess; J L Doppman; P H Sugarbaker; Richard I Fisher; timothy o'leary; D C Chatterji; G Grimes; R H Adamson; M Willis; B K Edwards
Computed tomography of the liver and spleen with intravenous lipoid contrast material: review of 60 examinations.
AJR. American journal of roentgenology 1982;138(6):1063-71.
1982: B A Silver; A L Barlock; Marc Lippman; T Anderson; Richard I Fisher
Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors.
Cancer treatment reports 1982;66(5):1229-30.
1982: Richard I Fisher
Implications of persistent T cell abnormalities for the etiology of Hodgkin's disease.
Cancer treatment reports 1982;66(4):681-7.
1982: C P Vanhaelen; Richard I Fisher
Increased sensitivity of T cells to regulation by normal suppressor cells persists in long-term survivors with Hodgkin's disease.
The American journal of medicine 1982;72(3):385-90.
1982: Arnold J Levine; Murray F Brennan; A Ramu; Richard I Fisher; P A Pizzo; D L Glaubiger
Controlled clinical trials of nutritional intervention as an adjunct to chemotherapy, with a comment on nutrition and drug resistance.
Cancer research 1982;42(2 Suppl):774s-781s.
1981: K C Micetich; M Jensen-Akula; J C Mandard; Richard I Fisher
Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.
The American journal of medicine 1981;71(6):967-72.
1981: Richard I Fisher; W D Terry; Richard J Hodes; STEVEN ROSENBERG; R Makuch; H G Gordon; S G Fisher
Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
The Surgical clinics of North America 1981;61(6):1267-77.
1981: M Vermess; M E Bernardino; J L Doppman; Richard I Fisher; J L Thomas; W S Velasquez; L M Fuller; A Russo
Use of intravenous liposoluble contrast material for the examination of the liver and spleen in lymphoma.
Journal of computer assisted tomography 1981;5(5):709-13.
1981: C P Vanhaelen; Richard I Fisher
Increased sensitivity of lymphocytes from patients with Hodgkin's disease to concanavalin A-induced suppressor cells.
Journal of immunology (Baltimore, Md. : 1950) 1981;127(3):1216-20.
1981: C P Vanhaelen; Richard I Fisher; E Appella; Lata Ramanathan
Lack of histocompatibility antigens on a murine ovarian teratocarcinoma.
Cancer research 1981;41(8):3186-91.
1981: M B Popp; Richard I Fisher; R Wesley; R Aamodt; Murray F Brennan
A prospective randomized study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma: influence on survival.
Surgery 1981;90(2):195-203.
1981: R F Ozols; Richard I Fisher; T Anderson; R Makuch; R C Young
Peritoneoscopy in the management of ovarian cancer.
American journal of obstetrics and gynecology 1981;140(6):611-9.
1981: Richard I Fisher; S M Hubbard; V T DeVita; C W Berard; R Wesley; J Cossman; R C Young
Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.
Blood 1981;58(1):45-51.
1981: Richard I Fisher; C Vanhaelen; F Bostick
Increased sensitivity to normal adherent suppressor cells in untreated advanced Hodgkin's disease.
Blood 1981;57(5):830-5.
1981: Richard I Fisher; R B Jones; V T DeVita; R M Simon; A J Garvin; C W Berard; R C Young
Natural history of malignant lymphomas with divergent histologies at staging evaluation.
Cancer 1981;47(8):2022-5.
1981: C P Vanhaelen; Richard I Fisher
Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.
Cancer research 1981;41(3):980-3.
1981: M B Popp; Richard I Fisher; R M Simon; Murray F Brennan
A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance.
Cancer treatment reports 1981;65 Suppl 5():129-35.
1980: M Vermess; J L Doppman; P Sugarbaker; Richard I Fisher; D C Chatterji; J Luetzeler; G Grimes; M Girton; R H Adamson
Clinical trials with a new intravenous liposoluble contrast material for computed tomography of the liver and spleen.
Radiology 1980;137(1 Pt 1):217-22.
1980: B A Chabner; Richard I Fisher; R C Young; V T DeVita
Staging of non-Hodgkin's lymphoma.
Seminars in oncology 1980;7(3):285-91.
1980: D M Morens; D J Bregman; C M West; M H Greene; M H Mazur; R Dolin; Richard I Fisher
An outbreak of varicella-zoster virus infection among cancer patients.
Annals of internal medicine 1980;93(3):414-9.
1980: N Reed Dunnick; Richard I Fisher; E W Chu; R C Young
Percutaneous aspiration of retroperitoneal lymph nodes in ovarian cancer.
AJR. American journal of roentgenology 1980;135(1):109-13.
1980: Richard I Fisher; V T DeVita; F Bostick; C Vanhaelen; D M Howser; S M Hubbard; R C Young
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.
Annals of internal medicine 1980;92(5):595-9.
1980: Richard I Fisher; G L Mandell; F Bostick; M G McMenamin; T Anderson
Chlorozotocin, an anti-tumour agent lacking bone marrow toxicity at therapeutic doses: effects on lymphocyte subpopulations in mice.
Clinical and experimental immunology 1980;39(2):416-25.
1979: R F Ozols; K R Grotzinger; Richard I Fisher; C E Myers; R C Young
Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer.
Cancer research 1979;39(8):3202-8.
1979: Richard I Fisher; V T DeVita; S P Hubbard; R Simon; R C Young
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.
Annals of internal medicine 1979;90(5):761-3.
1979: G L Mandell; Richard I Fisher; F Bostick; R C Young
Ovarian cancer: a solid tumor with evidence of normal cellular immune function but abnormal B cell function.
The American journal of medicine 1979;66(4):621-4.
1979: R C Young; D M Howser; T Anderson; Richard I Fisher; E Jaffe; V T DeVita
Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy.
The American journal of medicine 1979;66(3):435-43.
1979: R F Ozols; G Y Locker; James Doroshow; K R Grotzinger; C E Myers; Richard I Fisher; R C Young
Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.
Cancer treatment reports 1979;63(2):269-73.
1979: Richard I Fisher; B A Chabner; C E Myers
Phase II study of high-dose methotrexate in patients with advanced malignant melanoma.
Cancer treatment reports 1979;63(1):147-8.
1978: R C Young; B A Chabner; S P Hubbard; Richard I Fisher; R A Bender; T Anderson; R M Simon; George P Canellos; V T DeVita
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
The New England journal of medicine 1978;299(23):1261-6.
1978: B L Johnson; Richard I Fisher; R A Bender; V T DeVita; B A Chabner; R C Young
Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Cancer 1978;42(5):2157-61.
1978: R C Young; Richard I Fisher
The staging and treatment of epithelial ovarian cancer.
Canadian Medical Association journal 1978;119(3):249-56.
1978: N A Young; K J Kwon-Chung; T T Kubota; A E Jennings; Richard I Fisher
Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma.
Journal of clinical microbiology 1978;7(6):589-94.
1978: Richard I Fisher; T T Kubota; G L Mandell; S Broder; R C Young
Regression of a T-cell lymphoma after administration of antithymocyte globulin.
Annals of internal medicine 1978;88(6):799-800.
1978: K R Hande; Richard I Fisher; V T DeVita; B A Chabner; R C Young
Diffuse histiocytic lymphoma involving the gastrointestinal tract.
Cancer 1978;41(5):1984-9.
1978: Richard I Fisher; R C Young
Chemotherapy of ovarian cancer.
The Surgical clinics of North America 1978;58(1):143-50.
1978: R A Bender; T Anderson; Richard I Fisher; R C Young
Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma.
American journal of hematology 1978;5(3):203-9.
1977: K R Hande; R R Reimer; Richard I Fisher
Comparison of nodal primary versus extranodal primary histiocytic lymphoma.
Cancer treatment reports 1977;61(6):999-1000.
1977: T Anderson; R A Bender; Richard I Fisher; V T DeVita; B A Chabner; C W Berard; L Norton; R C Young
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Cancer treatment reports 1977;61(6):1057-66.
1977: V T DeVita; Richard I Fisher
Malignant melanoma: prognostic factors and therapeutic results.
The West Virginia medical journal 1977;73(8):167-72.
1977: Richard I Fisher; V T DeVita; B L Johnson; R Simon; R C Young
Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.
The American journal of medicine 1977;63(2):177-82.
1977: Richard I Fisher; R C Young
Advances in the staging and treatment of ovarian cancer.
Cancer 1977;39(2 Suppl):967-72.
1976: Richard I Fisher; E S Jaffe; R C Braylan; Judith C Andersen; H K Tan
Immunoblastic lymphadenopathy. Evolution into a malignant lymphoma with plasmacytoid features.
The American journal of medicine 1976;61(4):553-9.
1976: Richard I Fisher; J P Neifeld; Marc Lippman
Oestrogen receptors in human malignant melanoma.
Lancet 1976;2(7981):337-9.
1976: V T DeVita; Richard I Fisher
Natural history of malignant melanoma as related to therapy.
Cancer treatment reports 1976;60(2):153-7.
1976: J P Neifeld; Marc Lippman; Richard I Fisher
Receptors for steroid hormones in human melanoma.
Surgical forum 1976;27(62):108-10.
1975: P A Henkart; Richard I Fisher
Characterization of the lymphocyte surface receptors for Con A and PHA.
Journal of immunology (Baltimore, Md. : 1950) 1975;114(2 Pt 1):710-4.
1974: Richard I Fisher
Cognitive appraisal: an examination.
The Journal of psychology 1974;88(1st Half):147-52.
1974: H B Dickler; N FRANKLIN ADKINSON; Richard I Fisher; W D Terry
Lymphocytes in patients with variable immunodeficiency and panhypogammaglobulinemia. Evaluation of B and T cell surface markers and a proposed classification.
The Journal of clinical investigation 1974;53(3):834-40.